Zoetis Inc. (ZTS)
NYSE: ZTS · Real-Time Price · USD
77.25
+0.15 (0.19%)
At close: Sep 1, 2026, 4:00 PM EDT
77.48
+0.23 (0.30%)
Pre-market: Sep 2, 2026, 6:25 AM EDT
Zoetis Revenue
Zoetis had revenue of $2.47B in the quarter ending June 30, 2026, a decrease of -0.24%. This brings the company's revenue in the last twelve months to $9.52B, up 8.96% year-over-year. In the year 2025, Zoetis had annual revenue of $9.47B with 2.28% growth.
Revenue (ttm)
$9.52B
Revenue Growth
+8.96%
P/S Ratio
3.35
Revenue / Employee
$656,897
Employees
14,500
Market Cap
31.92B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.47B | 211.00M | 2.28% |
| Dec 31, 2024 | 9.26B | 712.00M | 8.33% |
| Dec 31, 2023 | 8.54B | 464.00M | 5.74% |
| Dec 31, 2022 | 8.08B | 304.00M | 3.91% |
| Dec 31, 2021 | 7.78B | 1.10B | 16.49% |
| Dec 31, 2020 | 6.68B | 415.00M | 6.63% |
| Dec 31, 2019 | 6.26B | 435.00M | 7.47% |
| Dec 31, 2018 | 5.83B | 518.00M | 9.76% |
| Dec 31, 2017 | 5.31B | 419.00M | 8.57% |
| Dec 31, 2016 | 4.89B | 123.00M | 2.58% |
| Dec 31, 2015 | 4.77B | -20.00M | -0.42% |
| Dec 31, 2014 | 4.79B | 224.00M | 4.91% |
| Dec 31, 2013 | 4.56B | 225.00M | 5.19% |
| Dec 31, 2012 | 4.34B | 103.00M | 2.43% |
| Dec 31, 2011 | 4.23B | 651.00M | 18.17% |
| Dec 31, 2010 | 3.58B | 822.00M | 29.78% |
| Dec 31, 2009 | 2.76B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 28.42B |
| Teva Pharmaceutical Industries | 17.32B |
| Haleon | 14.80B |
| Viatris | 14.74B |
| Elanco Animal Health | 5.02B |
| Dr. Reddy's Laboratories | 3.50B |
| Neurocrine Biosciences | 3.37B |
| United Therapeutics | 3.15B |
ZTS News
- 7 days ago - Zoetis price target lowered to $94 from $104 at TD Cowen - TheFly
- 12 days ago - Zoetis price target lowered to $80 from $85 at Stifel - TheFly
- 16 days ago - FDA issues Zoetis Emergency Use Authorization for Simparica TRIO for screwworm - TheFly
- 16 days ago - Zoetis confirms FDA Emergency Use Authorization for Simparica Trio - TheFly
- 19 days ago - Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies - Business Wire
- 19 days ago - Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs - Reuters
- 22 days ago - Zoetis price target lowered to $96 from $112 at Citi - TheFly
- 22 days ago - Zoetis price target lowered to $80 from $90 at Piper Sandler - TheFly